Filed 05 Aug 2026
- Price increases passed on to customers to mitigate RM inflation; margin recovery expected weighted towards H2 FY27.
- FY27 filings: 7 new APIs targeted; 10 product launches planned in formulations segment.
- Q2 expected to show sequential revenue improvement; year-on-year growth anticipated from H2 FY27.
- Oligonucleotide business (Sepala) targeting integrated offering and full ownership by FY30; 2.5x revenue growth in Q1.
- Specialty Chemicals skewed to H2 FY27 due to seasonality; aiming for double-digit growth from FY28.
- Q1 consolidated gross margin at 71.5% vs 73% YoY; impacted by product mix, lower pharma contribution, and higher freight/RM costs.